Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yarrow BioscienceYARW -2.78%13 14-Day RSI is 35.04 as of Sep. 14, 2026. GuruFocus rates YARW with a GF Score™ of 13/100. Among 1,418 Biotechnology companies, Yarrow Bioscience ranks better than 77.15% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Yarrow Bioscience 14-Day RSI Related Terms
YARW vs CGTX, RANI, VRCA: 14-Day RSI Comparison
For the Biotechnology subindustry, Yarrow Bioscience's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yarrow Bioscience 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Yarrow Bioscience's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a 14-Day RSI of 35.04 as of Sep. 14, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Yarrow Bioscience and its competitors. According to the industry distribution chart, Yarrow Bioscience ranks #324 out of 1418 companies in the Biotechnology industry, placing it in the top 22.8%.
Is Yarrow Bioscience's 14-Day RSI too high?
Yarrow Bioscience's current 14-Day RSI is 35.04. The Biotechnology industry median 14-Day RSI is 43.99. Yarrow Bioscience's value of 35.04 is 20.3% below this industry median. Based on the distribution chart, Yarrow Bioscience ranks #324 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's 14-Day RSI compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #324 out of 1418 companies for 14-Day RSI. This places Yarrow Bioscience in the top 23% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 43.99. Yarrow Bioscience's value of 35.04 is 20.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 43.99, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yarrow Bioscience's current 14-Day RSI of 35.04 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median 14-Day RSI is 43.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current 14-Day RSI is 35.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current 14-Day RSI of 35.04. The current 14-Day RSI is 35.04 and 20.3% below the Biotechnology industry median of 43.99. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current 14-Day RSI is 35.04 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
